Philip D Leighton, Age 86Menlo Park, CA

2005024, Nov 3, 2005

Mar 24, 2003

10/508808

Robert Etches - San Mateo CA, US
Robert Kay - San Francisco CA, US
Philip Leighton - San Francisco CA, US
Lei Zhu - Palo Alto CA, US

Origen Therapeutics - Buringame CA

A01K067/027
C12N005/06

800019000, 435349000

Human antibodies are produced in transgenic chickens having functional genetic components of the human immune system stably integrated in the genome. Techniques are described to integrate unrearranged human heavy and light chain immunoglobulin loci into the genome of the transgenic chicken. The functional description of the endogenous immunoglobulin loci yields an animal whose antibody repertoire in response to antigen is fully human. In the preferred embodiment, the human immunoglobulin locus is at least as large as the native human locus and exhibits functional class switching to yield IgG isotype antibodies. In addition to monoclonal antibodies secreted from immortalized B cell populations, polyclonal antibodies may be obtained from eggs laid by the transgenic chickens of the invention.

2006017, Aug 3, 2006

Feb 1, 2005

11/049229

Marie-Cecile Van de Lavoir - San Francisco CA, US
Philip Leighton - San Francisco CA, US

A01K 67/027
C12N 5/06

800019000, 435349000

The present invention is long-term cultures of avian PGCs and techniques to produce germline chimeric and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs produce germline chimeric birds. These germline chimeric birds do not have PGC derived somatic cells or tissues. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.

2006017, Aug 3, 2006

Aug 15, 2005

11/204879

Marie-Cecile Van de Lavoir - San Francisco CA, US
Philip Leighton - San Francisco CA, US

A01K 67/027
C12N 5/06

800019000, 435349000

The present invention is long-term cultures of avian PGCs and techniques to produce germline chimeric and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. These germline chimeric birds do not have substantial contributions of PGC-derived phenotypes in somatic cells or tissues. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.

2006020, Sep 14, 2006

Feb 1, 2006

11/346630

Marie-Cecile Van de Lavoir - San Francisco CA, US
Philip Leighton - San Francisco CA, US

A01K 67/027
C12N 5/06

800019000, 800004000, 435349000

The present invention is transgenic chickens obtained from long-term cultures of avian PGCs and techniques to produce and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.

2010013, Jun 3, 2010

Aug 14, 2008

12/192020

Marie-Cecile Van de Lavoir - San Francisco CA, US
Philip Albert Leighton - San Francisco CA, US

A01K 67/027
C12N 15/873

800 19, 800 21

The present invention is transgenic chickens obtained from long-term cultures of avian PGCs and techniques to produce and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. This invention includes compositions comprising long-term cultures of PGCs and offspring derived from them that are genetically modified. The genetic modifications introduced into PGCs to achieve the gene inactivation may also include, but are not restricted to, random integrations of transgenes into the genome, transgenes inserted into the promoter region of genes, transgenes inserted into repetitive elements in the genome, site specific changes to the genome that are introduced using integrase, site specific changes to the genome introduced by homologous recombination, and conditional mutations introduced into the genome by excising DNA that is flanked by lox sites or other sequences that are substrates for site specific recombination.

2011027, Nov 10, 2011

Jul 13, 2010

12/835721

Robert J. Etches - San Mateo CA, US
Robert M. Kay - San Francisco CA, US
Philip Leighton - San Francisco CA, US
Lei Zhu - Palo Alto CA, US

A01K 67/027
C12N 5/10
C12N 5/16

800 19, 435326

Human antibodies are produced in transgenic chickens having functional genetic components of the human immune system stably integrated in the genome. Techniques are described to integrate unrearranged human heavy and light chain immunoglobulin loci into the genome of the transgenic chicken.The functional description of the endogenous immunoglobulin loci yields an animal whose antibody repertoire in response to antigen is fully human.In the preferred embodiment, the human immunoglobulin locus is at least as large as the native human locus and exhibits functional class switching to yield IgG isotype antibodies. In addition to monoclonal antibodies secreted from immortalized B cell populations, polyclonal antibodies may be obtained from eggs laid by the transgenic chickens of the invention.

6248934, Jun 19, 2001

Nov 13, 1998

9/191652

Marc Tessier-Lavigne - San Francisco CA
William C. Skarnes - Berkeley CA
Kevin Mitchell - Albany CA
Philip A. Leighton - San Francisco CA

The Regents of the University of California - Oakland CA

C12N 1500
C12N 1509
C12N 1563
C12N 500

800 21

The invention provides methods and compositions for expressing targeted gene products in vertebrate neurons. The compositions include gene trap vectors comprising a polynucleotide comprising promoterless selectable marker and axon reporter encoding sequences, which may be operatively joined to an internal ribosome-entry site, and may comprise a splice acceptor site located 5' to the selectable marker and axon reporter encoding sequences. The methods include methods of expressing an axon reporter in a cell by transferring the subject vectors into an embryonic stem cell and incubating the cell under conditions whereby the cell or a progeny of the cell differentiates into a neuron comprising an axon or dendrites, and the neuron expresses the axon reporter under the transcriptional control of the gene; and specifically detecting the axon reporter in the axon or dendrites. Neuronal specific expression may also be effected in disclosed binary systems.

2019032, Oct 24, 2019

May 31, 2019

16/428763

- San Diego CA, US
Robert Etches - Oakland CA, US
Philip A. Leighton - San Francisco CA, US

A01K 67/027
C12P 21/02
C12N 15/85
C07K 16/00
C12N 15/87

A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.